The influence of Methylprednisolone and Erythropoietin to spinal cord injury:microarray data analysis

• Main Authors: Meng-Yu Tsai, 蔡孟瑜
• Other Authors: 李元綺
• Format: Others
• Language: zh-TW
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/92844672221757340793

碩士 === 臺北醫學大學 === 醫學資訊研究所 === 97 === Treatment of spinal cord injury (SCI) has been a frustrating endeavor in neurological medicine because SCI causes a series of devastating damage. The current treatment of SCI is restricted in the high-dose glucocorticoid drug. The anti-inflammatory therapy, Methylprednisolone (MP), is the currently accepted drug for acute SCI. Anti-inflammatory treatments in experimental studies have been shown to be useful on reducing inflammation and preserving spinal tissues for functional improvement. However, the high-dose MP in acute SCI induced a wide range of side effects in clinical trials, which is normally associated with higher incidence of infectious and metabolic complications in comparison to placebo or other treatments. In addition to MP, recent studies have investigated that Erythropoietin (EPO) can reduce the catastrophe of acute SCI and improve healing process after trauma. In the present study, we address time series gene expression alteration of spinal cord injury with or without MP or EPO treatment using large oligonucleotide microarray datasets. We illustrated the candidate biological pathways to explain the molecular interactions after treatments such as transcriptional regulation, protein-protein interactions, and phosphorylation. Finally, our analysis revealed significant molecular events of MP/EPO effects and provided potential pharmacological therapeutics that directed to rescue damaged tissue and regeneration in the injured spinal cord.